Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
COAG Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization of $75K in Q2 FY2026
Q2 FY2026 depreciation & amortization was $75K.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 304K USD
- Year-over-year change
- —
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 304K | — |
Depreciation & Amortization vs competitors
How COAG compares with its peers on the latest reported figures
- COAG's FY2025 depreciation & amortization of $304K is the 3rd highest of the 5 companies compared; the peer median is $226K.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13.19M | -9.3% | +20.0% | 72.9% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $358K | +78.1% | +46.7% | — |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $304K | — | — | — |
DMRADamora Therapeutics, Inc. | LTM Mar 2026 | $94K | -37.3% | -58.9% | — |
| LTM Mar 2026 | $67K | -46.0% | -18.0% | 7.8% | |
| Peer median (excluding COAG) | $226K | -23.3% | +1.0% | 40.3% | |
Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 0 |
| Gross Profit | 0 |
| Gross Margin | — |
| Research & Development | 59.63M |
| Selling, General & Admin | 10.49M |
| Operating Expenses | 70.12M |
| Depreciation & Amortization | 304K |
| EBITDA | (69.82M) |
| EBITDA Margin | — |
| Operating Income | (70.12M) |
| Operating Margin | — |
| Interest Income | 1.97M |
| Interest Expense | 0 |
| Other Income / Expenses | 5.98M |
| Income Before Tax | (64.14M) |
| Pre-Tax Margin | — |
| Income Tax Expense | (227K) |
| Net Income | (63.91M) |
| Net Margin | — |
| EPS (Basic) | (2.33) |
| EPS (Diluted) | (2.33) |
| Weighted Avg Shares | 27.44M |
| Weighted Avg Shares (Diluted) | 27.44M |
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
Intrinsic Alpha fair value
Locked
Current Price
$39.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.